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Abstract 
Background. Gamma-hydroxybutyrate (GHB; or sodium oxybate) is an endogenous GHB-/GABAB 
receptor agonist. It is approved for the application in narcolepsy and has been proposed for potential 
treatment of Alzheimer’s and Parkinson’s disease, fibromyalgia, and depression, all of which involve 
neuro-immunological processes. Tryptophan catabolites (TRYCATs), the cortisol awakening response 
(CAR), and brain derived neurotrophic factor (BDNF) have been suggested as peripheral biomarkers 
of neuropsychiatric disorders. GHB has been shown to induce a delayed reduction of T helper and 
natural killer cell counts and alter basal cortisol levels, but GHB’s effects on TRYCATs, CAR and BDNF 
are unknown. 
Methods. Therefore, TRYCAT and BDNF serum levels as well as CAR and the affective state (Positive 
and Negative Affect Schedule, PANAS) were measured in the morning after a single nocturnal dose of 
GHB (50 mg/kg body weight) in 20 healthy male volunteers in a placebo-controlled, balanced, 
randomized, double-blind, cross-over design. 
Results. In the morning after nocturnal GHB administration, the TRYCATs indolelactic acid, 
kynurenine, kynurenic acid, 3-hydroxykynurenine, and quinolinic acid, the 3-hydroxykynurenine to 
kynurenic acid ratio and the CAR were significantly reduced (p<0.05-0.001, Benjamini-Hochberg 
corrected). The quinolinic acid to kynurenic acid ratio was reduced by trend. Serotonin, tryptophan, 
and BDNF levels as well as PANAS scores in the morning remained unchanged after nocturnal GHB 
challenge. 
Conclusions. GHB has postacute effects on peripheral biomarkers of neuropsychiatric disorders, 
which might be a model to explain some of its therapeutic effects in disorders involving neuro-
immunological pathologies (ClinicalTrials.gov: NCT02342366). 
 
Keywords: Gamma-hydroxybutyrate, GHB, TRYCATS, kynurenine pathway, Cortisol, BDNF, 
neuroinflammation, neuropsychiatric disorders 
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Significance statement: GHB is used medically and experimentally in neuropsychiatric disorders such 
as narcolepsy, Parkinson’s and Alzheimer’s disease, and depression. These disorders involve neuro-
immune and neuro-inflammatory processes, especially of the tryptophan catabolites (TRYCATs) 
pathway. We found that nocturnal GHB reduces next morning’s metabolite levels of the kynurenine 
branch of the TRYCAT pathway and the cortisol awakening response in healthy subjects. This may be 
a mechanism by which the drug exerts its clinical effects in above mentioned disorders.  
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Introduction  
Gamma-hydroxybutyrate (GHB, or sodium oxybate) is a short-chain fatty acid that occurs naturally in 
the mammalian brain (Bessman and Fishbein, 1963). It is a gamma-aminobutyric acid (GABA) 
metabolite that binds as an agonist with high affinity to so-called GHB receptors and with a much 
lower affinity to GABAB receptors (Benavides et al., 1982). GHB unfolds unique sleep-augmenting 
properties, and unlike other sleep medications, it has proven efficacy in the treatment of narcolepsy, 
a debilitating sleep-regulation disorder (Boscolo-Berto et al., 2012). Its potential to treat other 
neuropsychiatric disorders associated with insomnia is currently being investigated in patients 
suffering from Parkinson’s (Buchele et al., 2018) and Alzheimer’s disease (Klein et al., 2015), 
fibromyalgia (Spaeth et al., 2012) and depression (Mamelak, 2009; Bosch et al., 2012). Interestingly, 
insomnia does not only represent a cardinal symptom in those disorders, but is also being discussed 
as a main driver of pathological alterations in systems engaged with neuro-inflammation, stress 
processing and neuroplasticity (Maes, 2011; Maurovich-Horvat et al., 2014; Qin et al., 2016; Tsilioni 
et al., 2016; Decourt et al., 2017). Thus, it has been argued, that GHB may beneficially modulate the 
disease course, by restoring the homeostatic functions physiological sleep has on those systems 
(Mamelak, 2009; Bosch et al., 2012). Interestingly, neuro-inflammation, stress processing and 
neuroplasticity have been found to be substantially related to each other, with inflammation being a 
key trigger of pathological alterations in the other. Several neuropsychiatric pathologies are 
characterized by increased levels of pro-inflammatory cytokines, excitotoxicity, oxidative stress and 
impaired mood (Maes et al., 2011). Thereby, an important downstream effect of increased pro-
inflammatory cytokine release is the activation of the kynurenine pathway (KYNP). The KYNP has 
been proposed as a biochemical hub, linking inflammatory processes, excitotoxicity and impaired 
mood in neuropsychiatric disorders (Maes et al., 2011). Activation of the KYNP triggers the 
degradation of tryptophan to partly neurotoxic metabolites, thereby reducing the available amount 
of serotonin in the brain, a major mood-stabilizing neurotransmitter (Maes et al., 2011). The entry 
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point of the KYNP are two rate-limiting enzymes: indoleamine 2,3-dioxygenase (IDO) and tryptophan 
dioxygenase (TDO) (Myint and Kim, 2014). IDO is activated by neuro-inflammatory processes, 
primarily by IFN- γ, but also by TNF-α (Takikawa et al., 1988; Pemberton et al., 1997). On the other 
hand, TDO is activated by psychophysiological stress via cortisol release (Myint and Kim, 2014). Both 
enzymes metabolize tryptophan to kynurenine, which is metabolized to kynurenic acid. This 
metabolic pathway constitutes the neuroprotective branch, because kynurenic acid acts as an 
antagonist at glutamatergic N-methyl-D-aspartate (NMDA) receptors and reduces glutamate-related 
neuronal excitotoxicity (Klein et al., 2013). There is also a neurotoxic branch, in which kynurenine is 
metabolized to 3-hydroxykynurenic acid and quinolinic acid. Both of these metabolites are supposed 
to be neurotoxic and oxidative stress inducing with depressogenic and anxiogenic effects, and serve 
as biomarkers for neurodegeneration (Maes et al., 2011). 
Moreover, inflammation has been related to enhanced cortisol secretion via the activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Bellavance and Rivest, 2014). The cortisol awakening 
response (CAR) represents a reliable method to assess HPA axis activity (Stalder et al., 2016), and has 
been shown to be increased in depression (Boggero et al., 2017). Intriguingly, increased HPA axis 
activity not only triggers the KYNP, but as well reduces levels of the brain derived neurotrophic factor 
(BDNF) (Masi and Brovedani, 2011), a neurotrophin which promotes neuroplasticity, and has been 
discussed to substantially contribute to the pathogenesis of above mentioned disorders (Lu et al., 
2014; Xu et al., 2015). Indeed, a possible mechanism of action of classical antidepressants may rely 
partly on the induction of BDNF expression and subsequent increased neuroplasticity (Autry and 
Monteggia, 2012). 
Interestingly, GHB unfolds immunomodulating and neuroprotective properties. In humans, it induces 
a delayed reduction of T helper and natural killer cell levels – both are activators of pro-inflammatory 
processes by releasing cytokines such as interferon gamma (IFN- γ) and tumor necrosis factor-alpha 
(TNF-α) (Pichini et al., 2010). In animals, GHB was shown to protect neuronal tissue against oxidative 
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stress (Gao et al., 2008). Moreover, GHB appears to have homeostatic regulatory effects on the HPA 
axis, this is, it increases blunted cortisol levels and reduces enhanced levels (Van Cauter et al., 1997; 
Nava et al., 2007). Despite its promising effects on neuro-immune processes, it is unknown to date, 
how a nocturnal dose of GHB affects downstream neuroinflammatory processes, such as the KYNP, 
BDNF expression, and HPA-axis activity on the next day.  
To this end, we here investigate the effects of a sleep-inducing dose of GHB (50 mg/kg p.o)  vs. 
placebo on morning serum levels of tryptophan catabolites (TRYCATs) including kynurenic acid, 
kynurenine, xanthurenic acid, 3-hydroxy-kynurenine, quinolinic acid, serotonin, and tryptophan and 
as well BDNF levels and the CAR in twenty healthy male volunteers. Additionally, the Positive and 
Negative Affect Schedule (PANAS) was applied to assess potential effects on mood. We used a 
postacute assessment, because the immunomodulating effects of GHB have been reported to start 
with a delay of 2-4 hours (Pichini et al., 2010), and nocturnal dosing followed by therapeutic effects 
during daytime is the standard pattern in the treatment of narcolepsy (Boscolo-Berto et al., 2012). 
The study followed a placebo-controlled, balanced, randomized, double-blind, cross-over design. In 
conclusion of the above mentioned effects of GHB on blood biomarkers of neuropsychiatric 
disorders, we expected that the drug would reduce KYNP metabolite levels and the CAR, while 
increasing serotonin, trypto han, and BDNF levels and enhance mood. 
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Materials and Methods  
Permission 
The study was approved by the Swissmedic and Cantonal Ethics Committee of Zurich and registered 
at ClinicalTrials.gov (NCT02342366). All participants provided written informed consent according to 
the declaration of Helsinki. 
 
Participants 
Twenty healthy, non-smoking, Caucasian, male students (mean age 25.8±2.45 yea s) participated in 
the study. Following criteria were required for inclusion: male sex to avoid the potential impact of 
menstrual cycle on blood chemical variables, age within the range of 18 to 30 years, absence of any 
somatic or psychiatric disorders, no first-degree relatives with a history of psychiatric disorders, non-
smoking, without a history of drug abuse (lifetime use > 5 occasions, with exception of occasional 
cannabis use). None of the participants reported previous experiences with GHB in their life. Before 
inclusion into the study, each subject was screened with all-night polysomnography in the sleep 
laboratory, to exclude sleep-related disorders such as sleep apnea, restless leg syndrome, sleep onset 
REM sleep, and insufficient sleep efficiency (< 80%). All participants were recruited via 
advertisements on the online student job platform of the University of Zurich. All subjects were 
monetary compensated for the completion of the study. 
 
Study design 
The study followed a placebo-controlled, randomized, balanced, cross-over design.  Two 
experimental nights were separated by a washout phase of seven days. Each experimental night was 
preceded by an adaptation night to habituate subjects to the laboratory environment.  
 
Figure 1 
Participants were instructed to refrain from illegal drugs for at least two weeks and from caffeine for 
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8 
one week prior to the first and until the second experimental night. No alcohol was allowed 24 h 
before each experimental night. Participants had to keep a regular sleep-wake rhythm with a 
bedtime of eight hours from 11:00 p.m. to 07:00 a.m. for one week prior to the first experimental 
night and during the week between the two experimental nights. To ensure adherence to these 
instructions, participants wore an actimeter on the non-dominant arm and kept a sleep-wake diary. 
All participants received a monetary compensation for the completion of the study. 
 
Drug administration 
GHB is currently the first-line, FDA-approved treatment for cataplexy and excessive daytime 
sleepiness in patients with narcolepsy (Boscolo-Berto et al., 2012). GHB-induced neuro-
immunological alterations were previously shown to start at 2-4 hours after ingestion (Pichini et al., 
2010). The drug is typically administered twice, an initial dose at bedtime and a second dose 2.5-4 
hours later, to stabilize the severely disturbed sleep continuity in narcolepsy patients (Boscolo-Berto 
et al., 2012). Therfore, a single oral dose of GHB was administered 3.5 hours after bedtime. All study 
participants were awoken at 02:30 am and received 50 mg/kg of GHB dissolved in 2 dl of orange juice 
and a placebo, matched in appearance and taste. Immediately after GHB ingestion, subjects were 
allowed to return to sleep. The used dose represents the starting dose used for the treatment of 
narcolepsy (Boscolo-Berto et al., 2012).  
 
Urine Drug S reening 
Urine samples were taken upon arrival in order to ensure that all participants abstained from illegal 
drug use (Drug-Screen Multi 12-AE, Nal von Minden GmbH, Regensburg, DE). Additional urine 
samples were collected in the morning following experimental nights to confirm GHB ingestion. 
Morning urine samples were analyzed with a cloned enzyme donor immunoassay (CEDIA®, Indiko 
plus, Thermo Fisher Scientific, San Jose, USA) for GHB with a cut-off concentration of 40 mg/L for 
GHB.  
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Blood collection 
Venous blood was sampled from the ante-cubital vein at 10:00 a.m. After a coagulation time of 30 
minutes, blood was centrifuged for 10 minutes at 2000 RCF to obtain clear serum. Supernatant 
serum was then distributed to Eppendorf tubes and immediately stored at -80°C. 
 
Tryptophan catabolites  
TRYCATs were analyzed using a ultra-high performance liquid chromatography (UHPLC) system 
(Thermo Fisher, San Jose, California, USA) coupled to a 5500 linear ion trap quadrupole mass 
spectrometer (Sciex, Darmstadt/Germany). The method was validated according to the guidelines of 
the German Society of Toxicology and Forensic Chemistry (GTFCh) (Peters et al., 2007). For details, 
see supplementary material. 
 
Cortisol awakening response  
Saliva of each subject was sampled at time points 7:00 (immediately after awakening), 7:15, 7:30, 
7:45, and 8:00 a.m. Thereby, subjects were instructed to chew the swab for 60 seconds and then 
return it in to the Salivette® tube (Sarstedt, Germany). After sampling, tubes were immediately 
stored on ice until final storage at -80°C. For cortisol detection, tubes were defrosted and centrifuged 
for 5 minutes at 5’000 rpm to yield clear saliva in the conical tube. Three subjects had to be excluded, 
as the amount of saliva yielded from the swabs was insufficient for further analysis. Then, the swab 
was removed and the yielded saliva was used for further analysis. A liquid-liquid extraction was 
carried out by adding 1.5 mL ethyl acetate to 265 μL of saliva sample and 50 µl IS (Cortison-D7 0.1 
ng/µL). The resulting mixture was subsequently shaken for 10 min at 5 Hz. The samples were 
centrifuged for 5 min at 9000 rpm and then placed in a freezer (-20° C) for approximately 60 min. The 
ethyl acetate layer was poured off and dried under nitrogen at 35° C. The dry residue was re-
suspended using 150 μL MeOH and 350 μL ammonium formate (5 mM) solution which was used for 
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10 
liquid chromatography-tandem mass spectrometry  (LC-MS/MS) analysis following a recently 
published method using 13C3-labeled cortisol as surrogate analyte for calibration (Binz et al., 2016). 
The method was validated according to the guidelines of the German Society of Toxicology and 
Forensic Chemistry (GTFCh) (Peters et al., 2007). The limit of detection for cortisol was 0.55 nmol/L 
and the limit of quantification was 1.1 nmol/L. 
 
Brain derived neurotrophic factor 
Quantification of serum BDNF levels was conducted at the Department of Clinical Psychology and 
Psychotherapy at the University of Zurich using a 96-Well MULTI-ARRAY® BDNF Assay (Meso-Scale 
Discovery, Rockville, Maryland). The analysis was performed according to the manufacturer’s 
instruction.  
 
Positive and Negative Affect Schedule 
Post-awakening mood was assessed at 10 a.m. using the PANAS, a questionnaire in which the 
participant is asked to rate the occurrence and intensity of 20 mood states (ten positive, ten negative 
adjectives) on a 5-point Likert scale in the moment of the rating (Watson et al., 1988). 
 
Statistical analysis 
All analyses were conducted using RStudio Version 1.0.136 (RStudio, Inc.). Three independent Linear 
Mixed Effects Models (LME) were used for TRYCATS, CAR, and BDNF levels. Posthoc testing was 
carried out using the R package emmeans (Version 1.2.1). Individual averages for each log-
transformed TRYCAT level and the 3-hydroxykynurenine to kynurenic acid and the quinolinic acid to 
kynurenic acid ratios were entered in a LME, whereas possible factors were condition (GHB vs. 
placebo) and metabolite (type of TRYCAT). Furthermore, statistical differences (p<0.05) of each 
TRYCAT was tested using post-hoc t-tests, applying Benjamini-Hochberg correction to adjust for 
multiple comparison (Hochberg and Benjamini, 1990). Individual log-transformed cortisol levels were 
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11 
entered in a LME, whereas possible factors were condition (GHB vs. placebo) and time point (7:00, 
7:15, 7:30, 7:45, 8:00 a.m.). Furthermore, statistical differences (p<0.05) in cortisol levels at each 
time point were tested using post-hoc t-tests, applying Benjamini-Hochberg correction to adjust for 
multiple comparison. Individual log-transformed BDNF levels were entered in a LME, with condition 
(GHB vs. placebo) as possible factors. Furthermore, statistical differences (p<0.05) in BDNF levels 
were tested using post-hoc t-tests, applying Benjamini-Hochberg correction to adjust for multiple 
comparison. 
For all applied models, normal Q-Q plots were applied, demonstrating normality of the residuals. 
Moreover, the assumption of homoscedasticity and linearity was verified using a Tukey-Anscombe 
(residuals vs fitted) plot. 
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Results 
Urine Drug Screening 
Drug screening revealed no positive test results for all subjects on both experimental nights. Morning 
urine analysis revealed a positive result for GHB exclusively in the drug condition of all investigated 
subjects. 
 
Tryptophan catabolites  
Statistical analysis revealed a significant main effect for condition (F(1,475)=28.81; p<0.001; 
η2=0.057). Posthoc tests further revealed reduced levels of indolelactic acid (p<0.01), kynurenine 
(p<0.05), kynurenic acid (p<0.01), 3-hydroxykynurenine (p<0.001), Quinolinic acid (p<0.001) and the 
3-hydroxykynurenine to kynurenic acid ratio (p<0.01) in the GHB condition compared to placebo 
(corrected for multiple comparisons). Tryptophan and the quinolinic acid to kynurenic acid ratio were 
reduced on a trend level (both p=0.085). All other metabolites remained unaffected by the drug. 
Results of statistical analysis are summarized in Table 1. 
 
 
  
Tryptophan catabolites levels (nM) and ratios  
 Placebo GHB    
Metabolites Mean SD Mean SD t-value Cohen’s d p-value 
Indolelactic acid 1100 180 990 160 -3.37 1.18 < 0.01 ** 
Serotonin 1000 370 940 370 -1.78 1.54 0.11 
Kynurenic acid  61 4.9 58 2.9 -4.28 0.75 < 0.01 ** 
Tryptophan 90000 13000 85000 8700 -2.05 0.75 0.085 
Kynurenine 2600 390 2400 380 -2.90 0.78 < 0.05 * 
Xanthurenic acid 25 7.9 36 49 0.97 -1.44 0.37 
3-Hydroxykynurenine 35 6.7 30 5.4 -6.00 1.53 < 0.001 *** 
Hydroxyindoleacetic acid 39 8.2 38 5.1 -0.86 0.65 0.40 
Quinolinic acid 450 100 410 97 -5.22 1.35 < 0.001 *** 
3-HK:KYNA ratio 0.57 0.09 0.53 0.09 -3.33 0.77 < 0.01 ** 
QUIN:KYNA ratio 7.4 1.6 7.0 1.7 -2.00 0.60 0.085 
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Figure 2 
 
Cortisol awakening response 
Statistical analysis revealed a significant main effect for condition (F(1, 125.41)=4.08; p<0.05; 
η2=0.029). Posthoc testing further revealed reduced cortisol levels at time points 7:00, 7:15 and 7:30 
a.m. in the GHB condition compared to placebo (corrected for multiple comparisons). By contrast, 
cortisol levels at time points 7:45 and 8:00 a.m. remained unaffected by the drug. 
 
Figure 3 
Brain derived neurotrophic factor 
Statistical analysis revealed no significant different BDNF levels between the GHB and the placebo 
condition (F(1,18.07)=0.29; p=0.59; η2=0.01). 
 
Figure 4 
 
Positive and Negative Affect Schedule 
Statistical analysis revealed no significant differences in the PANAS rating between the GHB and the 
placebo condition (F(1,56.99)=0.02; p=0.87; η2=0.0004).  
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Discussion 
Here, we investigated the effects of the mixed GHB-/GABAB receptor agonist GHB on peripheral 
biomarkers of neuropsychiatric disorders, assessing serum levels of TRYCATs and BDNF, as well as the 
CAR from saliva and subjective mood effects using the PANAS. We found that in healthy male 
subjects, a nocturnal dose of 50 mg/kg p.o. GHB reduces peripheral levels of the KYNP metabolites 
indolelactic acid, kynurenic acid, kynurenine, 3-hydroxykynurenine, and quinolinic acid 7.5 h after 
GHB intake, while BDNF, serotonin and tryptophan levels as well as PANAS scores remained 
unchanged. Moreover, GHB reduced the CAR 4,5 h after drug intake.  
Sleep disturbances represent a cardinal symptom in several neuropsychiatric disorders (Khurshid, 
2018) and may represent a main driver of pathological alterations in systems engaged with neuro-
inflammation, stress processing and neuroplasticity (Krysta et al., 2017; Irwin and Piber, 2018; Irwin 
and Vitiello, 2019)). GHB is an internationally established treatment of narcolepsy, but is also 
experimentally used and investigated to treat Parkinson’s (Buchele et al., 2018) and Alzheimer’s 
disease (Klein et al., 2015), as well as depression (Mamelak, 2009; Bosch et al., 2012). The 
therapeutic efficiency of GHB in these disorders is classically attributed to its unique sleep 
consolidating effects, as evening/nocturnal doses of the drug strongly increase deep sleep and 
reduce daytime sleepiness and fatigue during the next day (Van Cauter et al., 1997; Buchele et al., 
2018; Dornbierer et al., 2019). Given the important relationship between sleep and neuro-
immunological functioning, it has been argued, that GHB may beneficially modulate neuro-
inflammation and its downstream effects, by restoring sleep’s regenerating functions on the immune 
system (Gao et al., 2008; Mamelak, 2009; Klein et al., 2015).  
An important pro-inflammatory downstream effect of increased cytokine release is the activation of 
the KYNP and has been proposed as biochemical hub, linking inflammatory processes and impaired 
mood in neuropsychiatric disorders (Anderson and Maes, 2014; Maes and Anderson, 2016; Ogyu et 
al., 2018). The metabolization of tryptophan down the KYNP is initiated by the enzymes IDO and 
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TDO, thereby reducing neuronal levels of tryptophan, serotonin, and melatonin. IDO is strongly 
activated by inflammatory cytokines such as IFN-γ and TNF-α, and inhibition of this rate-limiting 
enzyme prevents the development of inflammation-induced depression- and anxiety-like behaviors 
(O'Connor et al., 2009; Salazar et al., 2012). Moreover, the products of this process are partly 
neurotoxic and pro-inflammatory, such as 3-hydroxykynurenine and quinolinic acid (Chiarugi et al., 
2001). Intriguingly, in our study, GHB induced an inhibition of the putatively neurotoxic KYNP 
metabolites 3-hydroxykynurenine and quinolinic acid, but also of kynurenine and the putative 
neuroprotective kynurenic acid. Intriguingly, this effect outlived the acute drug phase, given the 
short half-life of GHB (30-50 min) and the late time point of blood sampling (t7.5h). Inhibition of the 
KYNP by GHB may occur on several levels, but most evidences point towards indirect interactions of 
the drug with the function of the two rate-limiting enzymes of tryptophan degradation, IDO and TDO.  
First, GHB was found to induce a delayed reduction of T helper and natural killer cell levels in humans 
(Pichini et al., 2010). These lymphocytes are major cytokine producers and it is likely that GHB 
reduces the plasma cytokine load via this mechanism. Second, direct GABAB receptor stimulation of 
astrocytes (Gould et al., 2014) and microglia (Kuhn et al., 2004) were likewise found to reduce the 
release of the pro-inflammatory cytokines TNF-α and IL-6, both of which were identified as the most 
reliable inflammatory biomarkers of major depression (Miller and Raison, 2016). The IDO gene is 
predominantly activated by IFN-γ, whereas TNF-α synergistically increases the transcriptional 
stimulation of IDO synthesis in response to IFN-γ by up to 300% (Robinson et al., 2005). A third 
mechanism, by which GHB might indirectly inhibit IDO activity, is via increased progesterone release 
(Bosch et al., 2015).  Progesterone attenuates IFN- γ-mediated KYNP metabolite synthesis in human 
macrophages in vitro, leading to decreased levels of quinolinic acid and increased kynurenic acid 
levels (de Bie et al., 2016). Thus, GHB-induced lymphocyte reduction and astrocyte activation might 
reduce cytokine levels and thus IDO activity, while progesterone release seems to directly inhibit 
neurotoxic KYNP metabolite formation in macrophages. 
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The other rate-limiting enzyme of the KYNP is TDO. Reduction of TDO activity was early hypothesized 
to be an antidepressant treatment mechanism (Lapin and Oxenkrug, 1969), as TDO degrades 
approximately 99% of tryptophan in the periphery (Watanabe et al., 1980). Although TDO activity is 
generally stable and mainly controlled by the tryptophan level itself, stress-related cortisol release 
can enhance TDO degradation of tryptophan (Nakamura et al., 1987). The GHB-induced CAR 
reduction found in our study,  indicates a down-regulation of HPA axis activity and may be another 
mechanism by which the drug inhibits the KYNP. In fact, enhancement of IDO activity by cytokines 
and enhancement of TDO activity by cortisol are hypothesized to be the core mechanisms of KYNP 
metabolite mediated degenerative neuropsychiatric disorders (Myint and Kim, 2014), and both seem 
to be inhibited by GHB in humans. 
The two putatively neurotoxic products of the KYNP are 3-hydroxykynurenine and quinolinic acid. 
The serum levels of both molecules were reduced the next morning after GHB ingestion in our 
subjects. 3-hydroxykynurenine is a free radicals producer potentially involved in the mediation of 
oxidative stress and neuronal cell death (Chiarugi et al., 2001). Furthermore, 3-hydroxykynurenine 
can cause oxidative protein damage by generating superoxide and hydrogen peroxide (Goldstein et 
al., 2000). Several studies found associations of 3-hydroxykynurenine with neuropsychiatric and 
neurodegenerative pathologies: Memory deficits were associated with the molecule in patients with 
bipolar (Platzer et al., 2017) and major depressive disorder (Young et al., 2016). One study with 20 
patients suffering from Alzheimer’s disease revealed elevated 3-hydroxykynurenine plasma levels 
compared to controls (Schwarz et al., 2013). Another study with 48 patients with Parkinson’s disease, 
found an increase of 3-hydroxykynurenine by 30% in a metabolomics analysis of cerebrospinal fluid 
(Lewitt et al., 2013). 
The other potentially neurotoxic KYNP metabolite, quinolinic acid, acts as an agonist at NR2A and 
NR2B subtypes of glutamatergic NMDA receptors and thereby mediates excitotoxicity (de Carvalho 
et al., 1996). It is also a free radicals producer, as it induces nitric oxide synthase and excessive nitric 
oxide-mediated free radical damage (Braidy et al., 2009). As with 3-hydroxykynurenine, elevated 
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quinolinic acid (Guillemin et al., 2005) and kynurenic acid  (Jacobs et al., 2019) levels were associated 
with Alzheimer’s disease, Parkinson’s disease (Nemeth et al., 2006), and depression (Ogyu et al., 
2018). 
The pathophysiological role of indolelactic acid, which was also reduced by GHB in our participants, is 
still unclear. Some evidences point towards increased indolelactic acid in liver toxicity (Manna et al., 
2010). 
Not only neurotoxic KYNP metabolites such as quinolinic acid and 3-hydroxykynurenine, but also the 
putatively neuroprotective KYNP metabolite kynurenic acid was reduced after GHB administration in 
our participants. This was most likely due to an inhibition on the IDO and TDO activity, as all three 
molecules are downstream metabolites of these enzymes. However, it seems that this inhibition is 
stronger on the neurotoxic KYNP branch, as GHB also reduced the 3-hydroxykynurenine to kynurenic 
acid ratio significantly and the quinolinic acid to kynurenic acid ratio by trend. A comparable effect 
was already shown after electroconvulsive therapy (Guloksuz et al., 2015) and after antidepressant 
medication (Kocki et al., 2012) in depression. 
Anti-oxidative effects of GHB are well-established, as the drug limits the damage caused by reactive 
oxygen species, lipid peroxides, and other reactive molecules (for review see (Mamelak, 2007)). 
However, reduction of oxidative stress via inhibition of 3-hydroxykynurenine and/or quinolinic acid 
has not been documented to date. It was shown that GABAB agonism reduces excitatory 
glutamatergic neurotransmission in the brain (Chalifoux and Carter, 2011). So, GHB seems to inhibit a 
major source of neuroinflammation-induced excitotoxicity and via GABAB agonism also the target 
receptor of excitotoxic molecules. 
Further evidence for a modulation of human neuroendocrine and neuro-immune pathways by GHB is 
given by our finding that the drug reduces saliva CAR. The stress hormone cortisol is the end product 
of the HPA axis, and the CAR reflects the steep increase of cortisol occurring immediately after 
awakening. Diverse factors such as psychological functioning, psychiatric disorders, and alterations of 
the sleep-wake cycle have an impact on the CAR, but there is considerable heterogeneity in the 
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literature (Elder et al., 2014). However, evidences from meta-analyses point to associations of 
depression, stress and elevated vigilance with high and history of posttraumatic stress, fatigue, as 
well as schizophrenia with low cortisol output (Chida and Steptoe, 2009; Boggero et al., 2017). 
Consequently, GHB-induced CAR reduction may be interpreted in line with potential antidepressant 
and stress-reducing effects of the drug.  
Another disease relevant biomarker, which has been found to be affected by increased inflammation 
and psychophysiological stress is BDNF (Masi and Brovedani, 2011; Calabrese et al., 2014). It is a 
neurotrophin which promotes neuroplasticity, and has been discussed to substantially contribute to 
the pathogenesis of neuropsychiatric disorders (Lu et al., 2014; Xu et al., 2015). Despite the 
modulatory effects of GHB on the KYNP and CAR observed in this study, we did not find any drug 
effects on BDNF levels. Several reasons may account for this, such that changes in BDNF levels rely on 
the induction/inhibition of the BDNF gene expression, which may take several days or weeks to 
occur, as it is the case for antidepressants (Autry and Monteggia, 2012). Moreover, it is not fully 
understood how peripheral blood levels of BDNF related to its concentration the central nervous 
system. 
Subjective mood was assessed using the PANAS, but no significant postacute drug effect was found. 
As we tested the drug in healthy participants, a potential antidepressant effect was not addressed. 
However, overall tolerability of GHB was good, and no severe adverse effects occurred.  
Anyhow, our study has limitations. First, it was performed with healthy volunteers and not in a 
clinical sample. Therefore, further studies with patients suffering from neuropsychiatric disorders 
involving neuro-immune pathologies should be performed to test if GHB induces the same effects on 
TRYCATs and CAR along with therapeutic effects in these subjects. Second, we only applied a single 
dose of GHB instead of a continuous treatment as it is usually used in narcolepsy patients. Studies 
with repeated dosing should evaluate the course of blood levels of TRYCATs and BDNF and the CAR 
during GHB treatment in healthy participants and patient populations. 
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In summary, in healthy volunteers, a single nocturnal dose of GHB significantly reduces post-
awakening serum levels of several KYNP metabolites, including indolelactic acid, kynurenine, 
kynurenic acid, 3-hydroxykynurenine, quinolinic acid, as well as the 3-hydroxykynurenine to 
kynurenic acid ratio. Moreover, CAR was significantly reduced. These effects are most likely mediated 
by indirect inhibition of the rate-limiting enzymes of the KYNP, IDO and TDO. IDO may be inhibited 
via multiple mechanisms that reduce the serum cytokine load, while TDO seems to be inhibited via 
reduction of HPA axis activity. These effects show that GHB modulates neuro-inflammatory and 
neuro-immune pathways in humans and suggest that this mechanism may be responsible for its 
existing and potential therapeutic effects in neuropsychiatric and neurodegenerative disorders 
including narcolepsy, depression, as well as Alzheimer’s and Parkinson’s disease. 
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Figure legends: 
Figure 1: Session design. 
Figure 2: TRYCATs serum concentrations at time point 3h post-awakening/ 7.5 h post-GHB 
challenge placebo vs. GHB. 3HK: hydroxykynurenine, KYNA: Kynurenic acid. ***p<.001, 
**p<.01, *p<.05 (Benjamini-Hochberg correction). 
 
Figure 3: Cortisol awakening response (CAR) at time point 3h post-awakening/ 7.5 h post-
GHB challenge placebo vs. GHB. **p<.01, *p<.05 (Benjamini-Hochberg correction). 
 
Figure 4: Brain derived neurotrophic factor BDNF serum levels at time point 3h post-
awakening/ 7.5 h post-GHB challenge placebo vs. GHB.  
 
Table 1: Means, standard deviations (SD) of assessed metabolites, for the placebo and GHB 
condition (N=20). 3HK: 3-hydroxykynurenine, KYNA: kynurenic acid, QUIN: quinolinic acid. 
***p<.001, **p<.01, *p<.05 (Benjamini-Hochberg correction). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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